- call +1-201-465-4211
- email sales@mrinsights.biz
Treatment of patients with obstructive benign prostatic hypertrophy (BPH) with the drug Finasteride leads to a moderately improved urinary flow, symptomatic improvement and halts the natural progress of the disease
Scope of the Report:
This report studies the Benign Prostatic Hyperplasia Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Benign Prostatic Hyperplasia Therapeutics market by product type and applications/end industries.
The growth of the global benign prostatic hyperplasia therapeutics market is majorly driven by the increase in male geriatric population. Other factors boosting the market growth include rise in awareness about prostate cancer and other urological disorders and increase in occurrence of benign prostatic hyperplasia patients across the world. However, inclination of patients toward minimally-invasive surgeries namely, laparoscopic prostatectomy, transurethral needle ablation (TUNA), and transurethral microwave thermotherapy (TUMT), hampers the market growth. Conversely, presence of strong pipeline products and high potential in untapped markets of the emerging economies are expected to provide lucrative growth opportunities for the global benign prostatic hyperplasia therapeutics market.
The global Benign Prostatic Hyperplasia Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Benign Prostatic Hyperplasia Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Abbott Laboratories
Allergan plc
Astellas Pharma
Boehringer Ingelheim Pharma GmbH & Co. KG
Eli Lilly and Company
GlaxoSmithKline plc
Merck & Co.
Pfizer
Sanofi
Teva Pharmaceutical Industries Limited
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Alpha blocker
5-Alpha reductase inhibitor
Phosphodiesterase-5 inhibitor
Others
Market Segment by Applications, can be divided into
Mono drug therapy
Combination drug therapy
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Benign Prostatic Hyperplasia Therapeutics Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia Therapeutics
1.2 Classification of Benign Prostatic Hyperplasia Therapeutics by Types
1.2.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Types in 2017
1.2.3 Alpha blocker
1.2.4 5-Alpha reductase inhibitor
1.2.5 Phosphodiesterase-5 inhibitor
1.2.6 Others
1.3 Global Benign Prostatic Hyperplasia Therapeutics Market by Application
1.3.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Mono drug therapy
1.3.3 Combination drug therapy
1.4 Global Benign Prostatic Hyperplasia Therapeutics Market by Regions
1.4.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Benign Prostatic Hyperplasia Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Benign Prostatic Hyperplasia Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Benign Prostatic Hyperplasia Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Benign Prostatic Hyperplasia Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Benign Prostatic Hyperplasia Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Benign Prostatic Hyperplasia Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 Abbott Laboratories
2.1.1 Business Overview
2.1.2 Benign Prostatic Hyperplasia Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Allergan plc
2.2.1 Business Overview
2.2.2 Benign Prostatic Hyperplasia Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Allergan plc Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 Astellas Pharma
2.3.1 Business Overview
2.3.2 Benign Prostatic Hyperplasia Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Boehringer Ingelheim Pharma GmbH & Co. KG
2.4.1 Business Overview
2.4.2 Benign Prostatic Hyperplasia Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Boehringer Ingelheim Pharma GmbH & Co. KG Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 Eli Lilly and Company
2.5.1 Business Overview
2.5.2 Benign Prostatic Hyperplasia Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 GlaxoSmithKline plc
2.6.1 Business Overview
2.6.2 Benign Prostatic Hyperplasia Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.7 Merck & Co.
2.7.1 Business Overview
2.7.2 Benign Prostatic Hyperplasia Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Merck & Co. Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.8 Pfizer
2.8.1 Business Overview
2.8.2 Benign Prostatic Hyperplasia Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Pfizer Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.9 Sanofi
2.9.1 Business Overview
2.9.2 Benign Prostatic Hyperplasia Therapeutics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Sanofi Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.10 Teva Pharmaceutical Industries Limited
2.10.1 Business Overview
2.10.2 Benign Prostatic Hyperplasia Therapeutics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Benign Prostatic Hyperplasia Therapeutics Market Competition, by Players
3.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Benign Prostatic Hyperplasia Therapeutics Players Market Share
3.2.2 Top 10 Benign Prostatic Hyperplasia Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Benign Prostatic Hyperplasia Therapeutics Market Size by Regions
4.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue and Market Share by Regions
4.2 North America Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
5 North America Benign Prostatic Hyperplasia Therapeutics Revenue by Countries
5.1 North America Benign Prostatic Hyperplasia Therapeutics Revenue by Countries (2013-2018)
5.2 USA Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Countries
6.1 Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Countries
7.1 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Countries (2013-2018)
7.2 China Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
8 South America Benign Prostatic Hyperplasia Therapeutics Revenue by Countries
8.1 South America Benign Prostatic Hyperplasia Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Benign Prostatic Hyperplasia Therapeutics by Countries
9.1 Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2013-2018)
10 Global Benign Prostatic Hyperplasia Therapeutics Market Segment by Type
10.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Benign Prostatic Hyperplasia Therapeutics Market Forecast by Type (2018-2023)
10.3 Alpha blocker Revenue Growth Rate (2013-2023)
10.4 5-Alpha reductase inhibitor Revenue Growth Rate (2013-2023)
10.5 Phosphodiesterase-5 inhibitor Revenue Growth Rate (2013-2023)
10.6 Others Revenue Growth Rate (2013-2023)
11 Global Benign Prostatic Hyperplasia Therapeutics Market Segment by Application
11.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Benign Prostatic Hyperplasia Therapeutics Market Forecast by Application (2018-2023)
11.3 Mono drug therapy Revenue Growth (2013-2018)
11.4 Combination drug therapy Revenue Growth (2013-2018)
12 Global Benign Prostatic Hyperplasia Therapeutics Market Size Forecast (2018-2023)
12.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size Forecast (2018-2023)
12.2 Global Benign Prostatic Hyperplasia Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Benign Prostatic Hyperplasia Therapeutics Picture
Table Product Specifications of Benign Prostatic Hyperplasia Therapeutics
Table Global Benign Prostatic Hyperplasia
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
